CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Pharmaceutical Review Program Updates (CDR Update 133 and pCODR Update 63)

Published on: February 13, 2018
Result type: News

Today CADTH is pleased to announce operational changes that will enhance our Common Drug Review and pan-Canadian Oncology Drug Review programs. These changes reflect our careful consideration of stakeholder feedback and input from the participating jurisdictions. 

For complete details regarding the revised biosimilar review process and application fees, as well as additional program updates, please see:

To receive future updates and news from CADTH, please subscribe to our E-Alert